📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Natco Pharma Confirms Semaglutide Partnership with Eris Lifesciences for March 2026 Launch
Natco Pharma has confirmed its partnership with Eris Lifesciences for the marketing of the weight-loss drug Semaglutide in India. The company received CDSCO approval for the drug on February 14, 2026, and is preparing for a commercial launch in March 2026. While the company stated the partnership is in the ordinary course of business with no immediate material financial impact, it marks a significant entry into the high-growth GLP-1 segment. Natco is currently working with multiple marketing partners to facilitate this upcoming domestic launch.
Key Highlights
Received CDSCO approval for Semaglutide in India on February 14, 2026
Confirmed marketing partnership with Eris Lifesciences for the weight-loss drug
Product launch in the Indian market scheduled for March 2026
Company clarified that negotiations are part of ordinary business operations
💼 Action for Investors
Investors should monitor the revenue contribution from the Semaglutide launch starting Q1 FY27, as this segment represents a major growth opportunity. The ability to scale through multiple marketing partners like Eris could provide a competitive edge in the domestic market.
Natco Pharma Proposes Reappointment of CMD and CEO with Salary Caps up to ₹1.95 Crore
Natco Pharma is seeking shareholder approval via postal ballot for the reappointment of four key executive directors for a one-year term starting April 2026. The proposal includes Chairman V.C. Nannapaneni with a salary cap of ₹1.95 crore and CEO Rajeev Nannapaneni at ₹1.80 crore, both eligible for a 1% profit commission. Additionally, two other senior directors are proposed for reappointment with salaries up to ₹1.93 crore each. This move ensures leadership stability for the upcoming fiscal year while maintaining performance-linked incentives.
Key Highlights
Proposed reappointment of CMD V.C. Nannapaneni for 1 year with ₹1.95 crore salary plus 1% profit commission
Proposed reappointment of CEO Rajeev Nannapaneni for 1 year with ₹1.80 crore salary plus 1% profit commission
Directors P.S.R.K. Prasad and Dr. D. Linga Rao proposed for 1-year terms with salaries up to ₹1.93 crore each
Shareholder e-voting period scheduled from February 23, 2026, to March 24, 2026
Remuneration includes special incentives ranging from 20% to 100% of salary depending on the role
💼 Action for Investors
Investors should monitor the voting results to ensure leadership continuity; the short one-year tenure suggests a near-term review of leadership roles or potential succession planning.
Natco Pharma Q3 PAT at ₹151.3 Cr; Zero Revlimid Revenue; Eyes Large M&A with ₹2,500 Cr Cash
Natco Pharma reported a consolidated revenue of ₹705.4 crores for Q3 FY26, showing resilience despite zero revenue contribution from Revlimid during the quarter. The company is successfully pivoting towards emerging markets like Brazil and Canada while integrating its 35.75% stake in Adcock Ingram, which is expected to contribute ₹35-40 crores to quarterly PAT. Management is actively pursuing 1-2 large acquisitions using its ₹2,500 crore cash reserve and expects GLP-1 (Semaglutide) approval for the Indian market shortly. Additionally, the de-merger of the Crop Health Sciences business is on track for completion within the next 8-9 months.
Key Highlights
Consolidated revenue grew to ₹705.4 crores in Q3 FY26 compared to ₹651.1 crores in the previous year.
Maintained an EBITDA margin of 30.7% with a net profit of ₹151.3 crores despite zero Revlimid contribution.
Adcock Ingram acquisition expected to add approximately ₹35-40 crores to quarterly PAT moving forward.
Company holds a net cash position of ₹2,500 crores, earmarked for 1-2 large-scale acquisitions in 2026.
GLP-1 (Semaglutide) launch in India is imminent following expected DCGI approval and a fill-finish tie-up with OneSource.
💼 Action for Investors
Investors should monitor the progress of the Crop Health de-merger and the upcoming GLP-1 launch in India as key growth catalysts. The successful transition from Revlimid dependency to a diversified emerging market model strengthens the long-term investment case.
Natco Pharma Receives CDSCO Approval for Generic Semaglutide Injection in India
Natco Pharma has received regulatory approval from the CDSCO to manufacture and market generic Semaglutide injection in India. The drug is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. The company plans to launch the product in the domestic market in March 2026. This approval allows Natco to enter the high-demand GLP-1 receptor agonist segment, diversifying its portfolio beyond its traditional strength in oncology.
Key Highlights
Received CDSCO approval to manufacture and market generic Semaglutide injection in India
Commercial launch scheduled for the Indian market in March 2026
Product targets the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise
Leverages Natco's existing infrastructure of 9 manufacturing sites and 2 R&D facilities
💼 Action for Investors
Investors should view this as a significant portfolio expansion into the chronic care segment. Monitor the company's pricing strategy and market penetration following the March 2026 launch.
Natco Pharma Receives USFDA EIR with VAI Status for Chennai API Unit
Natco Pharma has received the Establishment Inspection Report (EIR) from the USFDA for its API manufacturing facility in Manali, Chennai. The inspection, which took place from November 17 to November 21, 2025, had originally resulted in seven Form-483 observations. The USFDA has now classified the inspection as Voluntary Action Indicated (VAI), meaning the facility is considered to be in a state of compliance. This resolution is a significant positive as it clears the path for future product approvals from this site.
Key Highlights
Received Establishment Inspection Report (EIR) for the Chennai API unit from the USFDA.
The inspection conducted in November 2025 resulted in 7 observations in Form-483.
USFDA has officially classified the inspection status as Voluntary Action Indicated (VAI).
The VAI status confirms that the facility meets regulatory standards despite the initial observations.
Clears regulatory hurdles for the API division which supports the company's oncology and specialty generic portfolio.
💼 Action for Investors
Investors should view this as a positive development that mitigates regulatory risk for Natco's API supply chain. The stock may see a positive reaction as the VAI status allows for uninterrupted business and new product approvals from the Chennai site.
Natco Pharma Declares 3rd Interim Dividend of Rs 1.50 per Share; Record Date Feb 18
Natco Pharma Limited has declared its third interim dividend of Rs 1.50 per equity share for the financial year 2025-26. This dividend represents a 75% payout on the face value of Rs 2 per share. The company has fixed February 18, 2026, as the record date to identify eligible shareholders for this payout. The distribution of the dividend is scheduled to begin on February 26, 2026.
Key Highlights
3rd interim dividend of Rs 1.50 per equity share (75% of face value) declared for FY 2025-26
Record date for dividend eligibility is set for February 18, 2026
Dividend payment process will commence from February 26, 2026
Announcement follows the Board of Directors meeting held on February 12, 2026
💼 Action for Investors
Investors interested in the dividend must own the shares before the ex-dividend date. Existing shareholders should verify their bank details are updated for seamless credit.
Natco Pharma Q3 PAT Up 14% YoY to ₹1,513M; Declares ₹1.50 Dividend & Chile Expansion
Natco Pharma reported a 14% YoY increase in consolidated net profit to ₹1,513 million for Q3 FY26, despite a significant sequential decline from Q2. The company declared a third interim dividend of ₹1.50 per share and announced the incorporation of a new subsidiary in Chile. A major milestone was the completion of the 35.75% stake acquisition in South Africa's Adcock Ingram for approximately $225 million. Additionally, the company is evaluating a demerger of its Agro Chemicals business and has appointed Amit Parekh as the new CFO.
Key Highlights
Consolidated Revenue from operations grew 36% YoY to ₹6,473 million, though down from ₹13,630 million in Q2.
Declared third interim dividend of ₹1.50 per share (75% of face value) with record date of Feb 18, 2026.
Completed acquisition of 35.75% stake in Adcock Ingram Holdings (South Africa) for ZAR 3,873 million (~$225 million).
Approved incorporation of a wholly-owned subsidiary in Chile with an investment of up to $300,000.
Appointed Amit Parekh as CFO effective Feb 13, 2026, following the superannuation of S.V.V.N. Appa Rao.
💼 Action for Investors
Investors should monitor the integration of the Adcock Ingram acquisition and the potential value unlocking from the proposed Agro Chemicals demerger. While YoY growth is positive, the high sequential volatility in earnings warrants a cautious approach to quarterly performance expectations.
Natco Pharma Appoints Amit Parekh as CFO and Kalakuntla Srinivas Rao as EVP Pharma Division
Natco Pharma has announced a leadership transition following the superannuation of its current CFO, Mr. S.V.V.N. Appa Rao, effective February 12, 2026. Mr. Amit Parekh, currently EVP of Finance and Accounts with 23+ years of experience including a tenure at Dr. Reddy's, will take over as CFO on February 13, 2026. Furthermore, the company has appointed Mr. Kalakuntla Srinivas Rao as EVP of the Pharma Division, bringing over 25 years of experience from MSN Laboratories and Lupin. These moves indicate a structured succession plan and a focus on strengthening operational leadership.
Key Highlights
Mr. S.V.V.N. Appa Rao to retire as CFO on February 12, 2026, after reaching superannuation.
Mr. Amit Parekh, with 23+ years of experience in finance and M&A, appointed as the new CFO effective February 13, 2026.
Mr. Kalakuntla Srinivas Rao appointed as EVP - Pharma Division with 25+ years of experience in USFDA and cGMP compliance.
New CFO Amit Parekh previously held senior finance roles at Dr. Reddy’s Laboratories and has expertise in IFRS and US GAAP.
EVP Kalakuntla Srinivas Rao has a proven track record in managing formulation operations and facility design.
💼 Action for Investors
This is a planned leadership transition and should be viewed as a routine corporate development. Investors should monitor if the new leadership introduces any shifts in financial strategy or operational focus in the coming years.
Natco Pharma Appoints Amit Parekh as CFO and Kalakuntla Srinivas Rao as EVP Pharma Division
Natco Pharma has announced a key leadership transition where Mr. Amit Parekh will take over as the Chief Financial Officer effective February 13, 2026, following the superannuation of Mr. S.V.V.N. Appa Rao. Mr. Parekh, currently an internal candidate, brings over 23 years of experience including a significant tenure at Dr. Reddy's Laboratories. Simultaneously, the company has appointed Mr. Kalakuntla Srinivas Rao as Executive Vice President of the Pharma Division, leveraging his 25+ years of experience in global regulatory compliance and operations. These appointments reflect a strategic move to bring in seasoned industry veterans to lead financial and operational functions.
Key Highlights
Mr. Amit Parekh appointed as CFO effective February 13, 2026, succeeding Mr. S.V.V.N. Appa Rao.
Incoming CFO Amit Parekh has over 23 years of experience in finance, M&A, and digital transformation.
Mr. Kalakuntla Srinivas Rao appointed as EVP - Pharma Division effective February 12, 2026.
New EVP brings 25+ years of experience with expertise in USFDA, PMDA, and MHRA compliance.
Leadership team strengthened with former executives from Dr. Reddy's, MSN Laboratories, and Lupin.
💼 Action for Investors
Investors should view this as a routine but important management transition; the internal promotion of the CFO suggests financial continuity while the new EVP brings valuable regulatory expertise.
Natco Pharma Q3 FY26 Net Profit Rises 14% to INR 1,513 Mn; Revenue Up 8% YoY
Natco Pharma reported a consolidated revenue of INR 7,054 Mn for Q3 FY26, an 8.3% increase over the previous year. Net profit grew 14.3% YoY to INR 1,513 Mn, aided by the strategic acquisition of a 35.75% stake in South Africa's Adcock Ingram. Export formulations continue to be the backbone of the business, contributing nearly 76% of the quarterly revenue. The company is also advancing its pipeline with 30 approved Para IVs and significant R&D investments in cell and gene therapy.
Key Highlights
Q3 FY26 Revenue reached INR 7,054 Mn compared to INR 6,511 Mn in Q3 FY25.
Net Profit stood at INR 1,513 Mn with an EPS of INR 8.46 for the quarter.
Export Formulations revenue grew to INR 4,214 Mn, representing 75.7% of total revenue.
Integration of Adcock Ingram (South Africa) contributed INR 109 Mn to the bottom line after amortization.
Robust pipeline includes 14 Solo FTFs and 30 approved Para IV products for the US market.
💼 Action for Investors
Investors should maintain a positive outlook given the strong 9-month performance (EPS of INR 64.24) and the potential of the US pipeline. Monitor the scaling of the Crop Health Sciences segment and the long-term impact of the South African acquisition.
Natco Pharma Q3 Net Profit Rises 14% YoY to ₹151 Cr; Declares ₹1.50 Interim Dividend
Natco Pharma reported a consolidated net profit of ₹1,513 million for Q3 FY26, marking a 14.3% growth year-on-year, though profits declined sharply on a sequential basis from ₹5,179 million in Q2. The company declared its third interim dividend of ₹1.50 per share for the fiscal year. Strategically, Natco completed a significant 35.75% stake acquisition in South Africa's Adcock Ingram for approximately $225 million and announced a new subsidiary in Chile. Management changes include the appointment of Amit Parekh as the new CFO following the retirement of S.V.V.N. Appa Rao.
Key Highlights
Consolidated Revenue from operations grew 36.3% YoY to ₹6,473 million in Q3 FY26.
Declared 3rd interim dividend of ₹1.50 per share (75% on face value of ₹2) with record date Feb 18, 2026.
Completed $225 million acquisition of 35.75% stake in Adcock Ingram Holdings, South Africa.
Board approved the incorporation of a wholly owned subsidiary in Chile with $300,000 investment.
Amit Parekh appointed as CFO effective Feb 13, 2026, succeeding the retiring S.V.V.N. Appa Rao.
💼 Action for Investors
Investors should focus on the successful integration of the Adcock Ingram acquisition and the potential value unlocking from the proposed Agro Chemicals demerger. While YoY growth is positive, the inherent quarterly volatility in Natco's earnings due to product-specific profit sharing requires a long-term investment horizon.
Natco Pharma Declares ₹1.50 Dividend; Q3 Net Profit Rises 14% YoY to ₹1,513 Million
Natco Pharma reported a steady performance for Q3 FY26, with consolidated revenue growing 36% YoY to ₹6,473 million. Net profit increased by 14% YoY to ₹1,513 million, supported by a ₹109 million contribution from its new South African associate, Adcock Ingram. The company declared its third interim dividend of ₹1.50 per share and announced the appointment of Amit Parekh as the new CFO. Strategic moves include a new subsidiary in Chile and the ongoing evaluation of a demerger for the Agro Chemicals business.
Key Highlights
Declared third interim dividend of ₹1.50 per equity share (75% of face value) with a record date of Feb 18, 2026.
Consolidated Revenue from operations rose to ₹6,473 million in Q3 FY26 from ₹4,748 million in Q3 FY25.
Net Profit for the quarter stood at ₹1,513 million compared to ₹1,324 million in the same period last year.
Completed acquisition of 35.75% stake in Adcock Ingram Holdings (South Africa) for ZAR 3,873 million (~$225 million).
Board approved the incorporation of a new wholly-owned subsidiary in Chile with an investment of up to $300,000.
💼 Action for Investors
Investors should monitor the integration of the Adcock Ingram acquisition and updates regarding the potential demerger of the Agro Chemicals segment. The steady dividend payout and international expansion remain positive indicators for long-term holders.
Natco Pharma Receives Tentative US FDA Approval for Generic Balversa; $60M Market Opportunity
Natco Pharma has received tentative approval from the U.S. FDA for Erdafitinib tablets, which is a generic version of Janssen Biotech's Balversa. The drug is used to treat adult patients with specific types of metastatic urothelial carcinoma. For the 12-month period ending September 2025, the reference drug had estimated sales of approximately $60 million in the U.S. market. This development is consistent with Natco's strategy of focusing on niche oncology products with limited competition in the United States.
Key Highlights
Received tentative U.S. FDA approval for Erdafitinib tablets in 3mg, 4mg, and 5mg strengths.
Generic version of Balversa, targeting locally advanced or metastatic urothelial carcinoma.
Reference drug annual U.S. sales estimated at $60 million as of September 2025.
Strengthens Natco's position as a leading oncology player in the U.S. generics market.
💼 Action for Investors
Investors should view this as a positive addition to Natco's U.S. pipeline, though the immediate financial impact is limited by the 'tentative' nature of the approval. Monitor for the transition to final approval and the subsequent commercial launch timeline.
Natco Pharma Gets Tentative USFDA Approval for Generic Balversa® with $60M Market Potential
Natco Pharma has received tentative approval from the USFDA for Erdafitinib tablets, a generic version of Janssen Biotech’s Balversa®. The drug is indicated for adult patients with specific types of metastatic urothelial carcinoma. According to industry data, Balversa® had estimated sales of approximately USD 60 million in the U.S. for the 12 months ending September 2025. This development aligns with Natco's core strategy of targeting limited-competition oncology products in the U.S. market.
Key Highlights
Received tentative USFDA approval for Erdafitinib in 3mg, 4mg, and 5mg strengths
Targets the U.S. market where the reference drug Balversa® generates ~$60 million in annual sales
The medication is used for treating advanced urothelial carcinoma with FGFR3 genetic alterations
Strengthens Natco's position as a specialized oncology player in the U.S. generic market
💼 Action for Investors
This is a positive development for the long-term pipeline; however, since it is a tentative approval, investors should wait for final approval and launch clarity. Maintain a positive outlook on the stock given its niche product focus.
Natco Pharma Acquires Remaining 49% Stake in Indonesian Subsidiary for ₹7.7 Crores
Natco Pharma's Singapore-based subsidiary has acquired the remaining 49% stake in PT NATCO Lotus Farma, making it a 100% owned entity. The acquisition was completed for a cash consideration of approximately ₹7.7 crores (IDR 14.07 billion). The Indonesian subsidiary reported a turnover of ₹2.7 crores for the period ending September 2025, showing growth from previous years. This consolidation allows Natco full control over its operations and expansion strategy in the Indonesian pharmaceutical market.
Key Highlights
Acquired 49% stake in PT NATCO Lotus Farma to reach 100% total ownership
Total cash consideration for the stake is approximately ₹7.7 crores (IDR 14.07 billion)
Target entity turnover increased to ₹2.7 crores for YTD Sep 2025 from ₹1.6 crores in FY25
The acquisition was completed at a par value of IDR 100,000 per share
💼 Action for Investors
This is a small-scale strategic consolidation that simplifies the corporate structure in Indonesia. Investors should monitor the growth of the Indonesian business as it scales from a low base.
Natco Pharma Clarifies Ongoing Patent Litigation Against Novo Nordisk
Natco Pharma has provided a clarification to the National Stock Exchange regarding news reports of its plea to revoke a patent held by Novo Nordisk. The company confirmed that the litigation has been ongoing for several months and is currently awaiting a final judicial outcome. Management stated that there is no material financial impact on the company at this stage. Natco has committed to informing the exchanges once a final decision is reached if it significantly impacts financial performance.
Key Highlights
Natco Pharma is seeking the revocation of a patent held by Novo Nordisk in the High Court.
The legal proceedings have been active for several months without a final verdict reached as of January 7, 2026.
The company currently reports no material financial impact resulting from the news article or the ongoing case.
Management maintains that all necessary disclosures under Regulation 30 of SEBI LODR are being followed.
💼 Action for Investors
Investors should monitor the final outcome of this patent challenge as a victory could allow Natco to launch generic versions of the drug, though no immediate financial impact is expected.
Natco Pharma FY25 Sustainability Report: ₹3,733M R&D Spend and 25% Renewable Energy Usage
Natco Pharma has released its Sustainability Report for FY 2024-25, highlighting a significant R&D investment of ₹3,733 million to drive its complex generics pipeline. The company achieved 25% renewable electricity usage and recycled 53% of its total water consumption, demonstrating strong progress in ESG metrics. Strategically, Natco maintains a robust US presence with 28 Para IV applications, 13 of which are already approved. The report also outlines long-term targets, including 100% carbon neutrality by 2050 and water neutrality for key API units by FY 2025-26.
Key Highlights
Invested ₹3,733 million in R&D, supporting a portfolio of 325 international and 115 Indian patents.
Achieved 25% renewable electricity consumption and recycled 53% of total water across manufacturing facilities.
Maintains a strong US pipeline with 28 Para IV applications, focusing on high-barrier complex generics.
Set ambitious environmental targets including 35% renewable energy by 2035 and full carbon neutrality by 2050.
Reported a global workforce of 5,000+ employees with a healthy retention rate of 85.73%.
💼 Action for Investors
Investors should note the high R&D intensity and strong Para IV pipeline as key drivers for future growth in the US and emerging markets. The company's improving ESG profile and debt-free status make it a resilient pick within the mid-cap pharma space.